Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

Renal impairment is associated with poor prognosis in myeloma. This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment. Transplant-ineligible patients not requi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Dimopoulos, Meletios A., Cheung, Matthew C., Roussel, Murielle, Liu, Ting, Gamberi, Barbara, Kolb, Brigitte, Derigs, H. Guenter, Eom, HyeonSeok, Belhadj, Karim, Lenain, Pascal, Van der Jagt, Richard, Rigaudeau, Sophie, Dib, Mamoun, Hall, Rachel, Jardel, Henry, Jaccard, Arnaud, Tosikyan, Axel, Karlin, Lionel, Bensinger, William, Schots, Rik, Leupin, Nicolas, Chen, Guang, Marek, Jennifer, Ervin-Haynes, Annette, Facon, Thierry
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2016
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815728/
https://ncbi.nlm.nih.gov/pubmed/26659916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.133629
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller